Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05910450 (SCALP1) for Alopecia, Androgenetic is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP1) Phase 3 703 Double-Blind
Within this study, the Clascoterone solution will be compared to a placebo.
The study has 2 parts:
Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up...
Show MoreA 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
- SCALP1
- CB-03-01/37
Androgenetic
Clascoterone solution
Phase 3
Randomized
Double-blind
Vehicle-controlled
AGA
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalClascoterone Part 1 and Part 2 Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study) | Clascoterone 5% solution Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples) |
OtherClascoterone Part 1 + Vehicle Part 2 Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle | Clascoterone 5% solution Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples) Vehicle solution Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples) |
OtherVehicle Part 1 + Clascoterone Part 2 Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution. | Clascoterone 5% solution Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples) Vehicle solution Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples) |
Placebo ComparatorVehicle Part 1 and Part 2 Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study) | Vehicle solution Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples) |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Changes in non-vellus Total Area Hair Count (TAHC) | Changes from Pivotal Part 1 Baseline in non-vellus Total Area Hair Count (TAHC) at Month 6. | 6 months |
Subject's assessment of own hair coverage | MAA-PRO item 8, a hair coverage-specific PGI-C, as the co-primary endpoint. The clinically meaningful change (threshold) is defined as a response of "1", "2", or "3".
Note that the item 2 responder threshold was used as a criterion for subjects to qualify for Part 2 enrollment. | 6 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Changes in non-vellus TAHC | Changes from Pivotal Part 1 Baseline in non-vellus TAHC at Month 3. | 3 months |
Changes in subject's assessment of satisfaction score | Changes in MAA-PRO SI (Male Androgenetic Alopecia-Patient Reported Outcomes Satisfaction Index) single treatment satisfaction item (item 15) score (i.e. question: "How satisfied are you with the study treatment?") at Month 6, with a minimum value of "Very dissatisfied" and a maximum value of "Very satisfied." | 6 months |
Subject can participate in this clinical study if all the following criteria are met:
- Subject who is male ≥18 years old.
- Subject who has provided written informed consent.
- Subject who has mild to moderate AGA in temple and vertex region, rating III vertex to V on the Modified Norwood-Hamilton Scale (i.e., III vertex \[IIIv\], IV, or V), with a history of ongoing hair loss.
- Subject who is willing to maintain the same hairstyle, hair length and hair color throughout the study.
- Subject who is willing to comply with study instructions at home and return to the clinic for required visits.
- Subject who agrees to continue his shampoo frequency and other general hair care products and regimen for the entire study.
- Subject who agrees to maintain same dietary and supplement pattern.
- Subjects who are sexually active with a female partner and are not surgically sterile (vasectomy performed at least 6 months prior to treatment) must agree to use an acceptable form of birth control as described in the informed consent form. For subjects, adequate forms of contraception include condom and spermicide in combination with other forms of female contraception. For females, an acceptable method (Pearl Index <1%) would be to agree to use implants, injectables, combined oral contraceptives, some intrauterine devices, or be postmenopausal (defined as amenorrhea greater than 12 consecutive months in women 50 years of age or older), be surgically sterile (hysterectomy, bilateral tubal ligation \[at least 6 months prior\], or bilateral oophorectomy).
Subjects who meet any of the following criteria are not eligible to participate in the study:
Subject who has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the IMP or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy.
Subject who has any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the IMP or requires use of interfering topical, systemic (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns), or surgical therapy.
Subject who has current or recent history (within 6 months) of hair weaves, non-breathable wigs, or hair bonding.
Subject who had scalp hair transplants at any time.
Subject with a history of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania, or conditions/diseases other than AGA.
Subject who has a current or recent history (within 6 months) of severe dietary or weight changes or has a history of eating disorder(s), any history of bariatric surgery (gastric bypass, gastric sleeve, stomach stapling); macro- or micro-nutrient deficiencies within the last 6 months (i.e.: clinically significant iron deficiency, protein deficiency confirmed by lab testing) and/or any current diagnosis of malabsorptive disease (i.e.: Celiac, Irritable Bowel disease etc.).
Subject who has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this study, including 12-lead electrocardiogram (ECG) findings during the screening period.
Subject is currently enrolled in an investigational drug or device study.
Subject who has used an investigational drug or investigational device treatment within 30 days or 5 half-lives whichever is longer prior to Visit 2/Baseline.
Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
Subject who has used or is suspected, in the investigator's opinion, to be using anabolic steroids.
Subject who may be unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, and/or subjects who will be unable to return for scheduled follow-up visits.
Subject who has a known hypersensitivity or previous allergic reaction to any of the active or inactive ingredients in the IMPs or tattoo ink.
Subject who has used any of the following topical preparations or procedures on the scalp:
- Topical scalp treatments for hair growth including minoxidil, Aminexil, hormone therapy, anti-androgens, or other agents that are known to affect hair growth within 12 weeks of Visit 2/Baseline.
- Topical scalp over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene, Nioxin, Foltene, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within 2 weeks of Visit 2/Baseline.
- Topical scalp treatments that may have ancillary effect on hair growth including, but not limited to, corticosteroids, pimecrolimus, tacrolimus, and retinoids within 4 weeks of Visit 2/Baseline.
- Scalp procedures (surgical, laser, light, or energy treatments, micro-needling, etc.) within 6 months of Visit 2/Baseline.
- Platelet rich plasma (PRP) procedure on the scalp within 6 months of Visit 2/Baseline.
Subject who has used one or more of the following systemic medications or procedures:
- Beta blockers, cimetidine, diazoxide, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2/Baseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable \[defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2/Baseline\].
- Retinoid, isotretinoin, vitamin A intake above 10,000 IU per day, or cyclosporine therapy within 6 months of Visit 2/Baseline.
- Any 5 alpha reductase medications (i.e.: Finasteride \[Propecia®, etc.\], Dutasteride or similar products within 6 months of Visit 2/Baseline.
- Chemotherapy or cytotoxic agents at any time.
- Radiation of the scalp at any time point.
- Other systemic therapy, which in the opinion of the investigator, may materially affect the subject's hair or hair growth, including, but not limited to, spironolactone, vitamin or homeopathy supplement hair growth or hair health products or other steroid hormones (in any form), including anabolic steroids during the 3 months prior to baseline or during the study.
Subject who has been previously enrolled in any study with Clascoterone (former CB 03 01).
Subject who is an employee or direct relative of an employee of the contract research organization (CRO), the study site, or the Sponsor.
Subject who is institutionalized because of legal or regulatory order.
Cassiopea SpA- 🏛️Ergomed PLC
Arkansas
California
Florida
Louisiana
Michigan
Minnesota
Nevada
New Jersey
New York
North Carolina
Texas